Copiktra Approval History
FDA Approved: Yes (First approved September 24, 2018)
Brand name: Copiktra
Generic name: duvelisib
Dosage form: Capsules
Company: Verastem, Inc.
Treatment for: Chronic Lymphocytic Leukemia, Follicular Lymphoma
Copiktra (duvelisib) is a first-in-class, oral, dual phosphoinositide-3-kinase (PI3K)-delta/PI3K-gamma inhibitor for the treatment relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and relapsed or refractory follicular lymphoma (FL).
Development History and FDA Approval Process for Copiktra
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.